Prediction of outcome using pretreatment 18F-FDG PET/CT and MRI radiomics in locally advanced cervical cancer treated with chemoradiotherapy
The aim of this study is to determine if radiomics features from 18fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) and magnetic resonance imaging (MRI) images could contribute to prognoses in cervical cancer.
One hundred and two patients (69 for training and 33 for testing) with locally advanced cervical cancer (LACC) receiving chemoradiotherapy (CRT) from 08/2010 to 12/2016 were enrolled in this study. 18F-FDG PET/CT and MRI examination [T1, T2, T1C, diffusion-weighted imaging (DWI)] were performed for each patient before CRT. Primary tumor volumes were delineated with the fuzzy locally adaptive Bayesian algorithm in the PET images and with 3D Slicer™ in the MRI images. Radiomics features (intensity, shape, and texture) were extracted and their prognostic value was compared with clinical parameters for recurrence-free and locoregional control.
In the training cohort, median follow-up was 3.0 years (range, 0.43–6.56 years) and relapse occurred in 36% of patients. In univariate analysis, FIGO stage (I–II vs. III–IV) and metabolic response (complete vs. non-complete) were probably associated with outcome without reaching statistical significance, contrary to several radiomics features from both PET and MRI sequences. Multivariate analysis in training test identified Grey Level Non UniformityGLRLM in PET and EntropyGLCM in ADC maps from DWI MRI as independent prognostic factors. These had significantly higher prognostic power than clinical parameters, as evaluated in the testing cohort with accuracy of 94% for predicting recurrence and 100% for predicting lack of loco-regional control (versus ~50–60% for clinical parameters).
In LACC treated with CRT, radiomics features such as EntropyGLCM and GLNUGLRLM from functional imaging DWI-MRI and PET, respectively, are independent predictors of recurrence and loco-regional control with significantly higher prognostic power than usual clinical parameters. Further research is warranted for their validation, which may justify more aggressive treatment in patients identified with high probability of recurrence.
KeywordsChemoradiotherapy Cervical cancer Radiomics Prediction FDG PET MRI
Compliance with ethical standards
Conflict of interest
All authors declare that they have no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
- 2.Rose PG, Java J, Whitney CW, Stehman FB, Lanciano R, Thomas GM, et al. Nomograms predicting progression-free survival, overall survival, and pelvic recurrence in locally advanced cervical cancer developed from an analysis of identifiable prognostic factors in patients from NRG oncology/Gynecologic oncology group randomized trials of chemoradiotherapy. J Clin Oncol : Off J Am Soc Clin Oncol. 2015;33(19):2136–42.CrossRefGoogle Scholar
- 3.Moore KN, Java JJ, Slaughter KN, Rose PG, Lanciano R, DiSilvestro PA, et al. Is age a prognostic biomarker for survival among women with locally advanced cervical cancer treated with chemoradiation? An NRG oncology/Gynecologic oncology group ancillary data analysis. Gynecol Oncol. 2016;143(2):294–301.CrossRefPubMedPubMedCentralGoogle Scholar
- 9.Ho KC, Fang YH, Chung HW, Yen TC, Ho TY, Chou HH, et al. A preliminary investigation into textural features of intratumoral metabolic heterogeneity in (18)F-FDG PET for overall survival prognosis in patients with bulky cervical cancer treated with definitive concurrent chemoradiotherapy. Am J Nuclear Med Molec Imaging. 2016;6(3):166–75.Google Scholar
- 14.Lim K, Small W Jr, Portelance L, Creutzberg C, Jurgenliemk-Schulz IM, Mundt A, et al. Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy for the definitive treatment of cervix cancer. Int J Radiat Oncol Biol Phys. 2011;79(2):348–55.CrossRefPubMedGoogle Scholar
- 19.Alex Zwanenburg SL, Martin Vallières, Steffen Löck. Image biomarker standardisation initiative - feature definitions. 2017.Google Scholar
- 20.Desseroit MC, et al. Comparison of three quantization methods for the calculation of textural features in PET/CT images: impact on prognostic models in non-small cell lung cancer. IEEE Nucl Sci Sym Med Imaging Conf 2016.Google Scholar
- 23.Naik A, Gurjar OP, Gupta KL, Singh K, Nag P, Bhandari V. Comparison of dosimetric parameters and acute toxicity of intensity-modulated and three-dimensional radiotherapy in patients with cervix carcinoma: a randomized prospective study. Cancer Radiotherapie : J de la Societe francaise de radiotherapie oncologique. 2016;20(5):370–6.CrossRefGoogle Scholar
- 30.Hatt M, Majdoub M, Vallieres M, Tixier F, Le Rest CC, Groheux D, et al. 18F-FDG PET uptake characterization through texture analysis: investigating the complementary nature of heterogeneity and functional tumor volume in a multi-cancer site patient cohort. J Nucl Med : Off Publ, Soc Nucl Med. 2015;56(1):38–44.CrossRefGoogle Scholar
- 33.Incoronato M, Aiello M, Infante T, Cavaliere C, Grimaldi AM, Mirabelli P, et al. Radiogenomic analysis of oncological data: a technical survey. Int J Mol Sci. 2017;18(4)Google Scholar
- 34.Cancer Genome Atlas Research N, Albert Einstein College of M, analytical biological S, Barretos cancer H, Baylor College of M, Beckman Research Institute of City of H, Buck Institute for research on a, Canada’s Michael smith genome sciences C, Harvard medical S, FGCC H, et al. Integrated genomic and molecular characterization of cervical cancer. Nature. 2017;543(7645):378–84.CrossRefGoogle Scholar